Graves Disease Treatment Market
Report ID: SQMIG35I2583
Report ID: SQMIG35I2583
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I2583 |
Region:
Global |
Published Date: March, 2026
Pages:
157
|Tables:
117
|Figures:
77
Global Graves Disease Treatment Market size was valued at USD 2.5 Billion in 2024 and is poised to grow from USD 2.64 Billion in 2025 to USD 4.05 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).
Key Takeaways : Market Trends & Insights
Growing prevalence of autoimmune thyroid disorders, increasing awareness and early diagnosis of hyperthyroidism, rising demand for effective treatment options, advancements in biologic therapies, and expanding healthcare access are driving sales of Graves disease treatment.
The growing acceptance of new drugs in the treatment of thyroid eye disease, providing more specific benefits, is generating new business opportunities. Following these trends, diversity in therapeutic approaches and affordability remain key factors, with biologicals and new chemical drugs gaining more prominence for hard-to-treat cases. The increased usage of advanced diagnostic techniques and tele-endocrinology has contributed to the early identification and start of therapy, particularly in emerging economies such as India and China, where spending on health care has been on the rise. Growing recognition of thyroid-related disorders among patients and healthcare providers, coupled with advancements in diagnostic technologies and treatment options, is expected to primarily drive Graves disease treatment market growth.
On the contrary, high treatment costs, potential side effects of therapies, limited access to advanced biologics in low-income regions, and challenges in long-term disease management are anticipated to slow down Graves disease treatment market penetration over the coming years.
How is AI Improving Patient Outcomes In The Graves Disease Treatment Market?
AI technology is improving the scope of Graves disease treatment by enhancing accuracy and timeliness of diagnosis and care. This includes analyzing CT, MRI scans, and physical attributes in the form of facial characteristics to identify thyroid eye disease and the level of its severity, resulting in more informed clinical decision-making. AI is able to make predictions regarding the effectiveness of the treatment for Graves disease based on patterns found within medical images. This minimizes discrepancies among physicians when interpreting findings from images.
In July 2025, Avant Technologies announced AI-driven ophthalmology initiatives, including a Vision AI pilot. This demonstrates how AI-based screening and image analysis can speed up detection of thyroid eye disease, improve referral processes, and support targeted use of advanced therapies, ultimately enhancing patient access and treatment outcomes.
Market snapshot - 2026-2033
Global Market Size
USD 2.5 Billion
Largest Segment
Antithyroid Drugs
Fastest Growth
Targeted Biologics
Growth Rate
5.5% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global Graves disease treatment market is segmented by therapy type, surgical intervention, clinical manifestation, end-user, and region. Based on therapy type, the market is segmented into antithyroid drugs, radioactive iodine therapy, beta-blockers, and targeted biologics. Based on surgical intervention, the market is segmented into total/partial thyroidectomy and orbital decompression. Based on clinical manifestation, the market is segmented into Hyperthyroidism Focus, Graves' Ophthalmopathy, and Graves' Dermopathy. Based on end-user, the market is segmented into endocrine specialty clinics, hospitals & tertiary care centers, and retail pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The Antithyroid drugs segment is estimated to spearhead the global Graves disease treatment market revenue generation in the future. These therapies represent the long-established frontline approach for managing thyrotoxicosis in Graves disease, offering oral administration, and clinician familiarity to cement their high share. Because of their reliable biochemical regulation, they are often used consistently in chronic and preoperative cases, impacting prescription tendencies and distribution strategies. Through consistent clinical recommendations and ease of implementation, they remain an important element, guiding financial and therapeutic considerations within endocrinology offices.
However, targeted biologics is emerging as the most rapidly expanding segment as per this Graves disease treatment industry analysis. Novel mechanism of action therapies that address difficult to treat manifestations and refractory cases create new business scope. Trends in regulation and solid clinical data are driving specialist uptake, resulting in targeted investments, expanded indications, and interdisciplinary cooperation that establish novel approaches to care and business models in treating Graves' disease.
The Hyperthyroidism focus segment is slated to account for the largest global Graves disease treatment market share going forward. Management of excess thyroid hormones is the primary clinical objective that shapes diagnostic pathways and therapy selection in Graves disease. The treatment methods, surveillance techniques, and care processes will be developed keeping euthyroidism in mind to prevent any systemic impacts, hence allocating funds towards endocrinology medicines, laboratory surveillance systems, and follow-up surveillance systems. As a result, there is a concentration on hormone regulation of product development and training.
At the same time, Graves' Ophthalmopathy shows great momentum of growth due to the development of biological drugs, surgical procedures, and approaches based on multidisciplinary cooperation. The development of services is stimulated by the growing interest in the field and the positive results of research, as well as by investments focused on developing these services.
To get detailed segments analysis, Request a Free Sample Report
Advanced clinical infrastructure, concentrated investment in endocrinology research, and rapid uptake of novel therapeutic approaches allow this region to lead Graves disease treatment adoption. High level of knowledge among both clinicians and patients, developed referral networks and excellent communication between payers & providers allow for timely access to specialty care. Outstanding academic centres and the use of integrative model of care support implementation of the best practice and quick application of evidence to Provide Routine Care. Pharmaceutical / Biotech companies provide tremendous support to create and commercialize their therapeutic drugs. The cooperative/regulatory environment and active patient advocates help support both the development and consistent use of evidence-based treatment guidelines and the implementation of evidence-based management strategies throughout North America.
Concentrated referral networks, leading academic centers, and broad availability of specialty care pathways allow the United States to lead demand outlook in this region. Advocacy for patient care and guideline formation reinforce these positive trends in the country. Established medical infrastructure and clinical research leads to quick implementation of treatment options and diagnostic measures. Payer models allow for accessibility to cutting-edge treatments, whereas multidisciplinary collaboration ensures individualized treatment strategies.
Integrated health systems, coordinated specialist referral pathways, and emphasis on equitable access to care support consistent Graves disease treatment demand in Canada. Public reimbursement mechanisms determine the availability of treatment modalities and drive standardization of management via guideline implementation. The interaction between academic centers, provincial programs, and industry facilitates clinical skills and adoption of new treatments. The structure of provincial programs provides the basis for training physicians to implement evidence-based practices.
Cohesive healthcare frameworks, strong clinical guidelines, and active collaboration among research institutions and industry makes Europe an opportune region going forward. Cross border and pan-regional clinical collaborations, together with professional societies, contribute to generating evidence and refining clinical guidelines. There is increasing engagement between payers, clinicians and patient organizations resulting in greater awareness of the innovations and the evaluation of these innovations within real world clinical contexts. A local pharmaceutical industry, local manufacturing capabilities and digital health initiatives increase the availability of specialist care throughout the various national markets within Europe. Harmonization of regulatory and reimbursement processes across multiple jurisdictions aids wider access to new therapeutics and standardised care pathways. There are many specialty endocrinology centres in Europe with a strong focus on multidisciplinary approaches to patients leading to greater adoption of advanced diagnostics and therapies.
Extensive network of endocrine centers, strong clinical research programs, and diagnostic support for care support consistent Graves disease treatment demand in Germany. Participation in joint European research programs and availability of a pharmaceutical base makes possible for the clinical testing and introduction of new medicines for the disease. Reimbursement models and guideline-driven pathways promote the incorporation of specialty drugs and multidisciplinary management approaches. The coordination between hospitals and outpatient specialists promotes consistency in treatment.
Robust primary care referral systems, integrated specialist clinics, and proactive guideline implementation shapes Graves disease treatment demand in the United Kingdom. Multidisciplinary approach to treatment, patient involvement, and digitized follow-ups improve care coordination. Collaborations between academic institutions, clinical organizations, and policymakers lead to rapid uptake of novel treatment protocols. The health care system enables patients to have access to advanced diagnostics and treatment facilities, whereas research groups assist in assessing new treatment modalities clinically.
Endocrine specialties, multidisciplinary approaches, and physician networks are influencing the demand for Graves' disease treatments in France. Academic institutions and pharmaceutical firms are collaborating in conducting clinical trials for new medications locally, and patients' associations are gaining more influence in promoting their adoption. National guidelines and regional initiatives encourage the standardization of diagnosis and treatment protocols. Collaboration among specialists within hospitals and clinics is facilitating treatment continuity and customization.
Targeted investments in clinical capacity, diagnostics, and collaborative research between local and international companies are governing Graves disease treatment demand in Asia Pacific. Major healthcare institutions throughout the region are increasing the availability of specialists in endocrinology, as well as developing new models of multidisciplinary care. Additionally, the growing adoption of digital health tools and advanced diagnostic tests will help support better monitoring and follow-up of patients and engage clinicians and patients in their treatment plans through education initiatives. In addition to these efforts, active engagement with health regulators and a rapidly developing biotechnology sector in the Asia Pacific region will continue to support the advancement of new clinical development and commercialization efforts. Emphasis on offering more comprehensive treatment options for patients and global innovation in therapeutic delivery systems are also creating new business scope in this region.
Advanced hospital facilities, advanced diagnostics, and research in academia are driving high demand for Graves disease therapies in Japan. Technology deployment in diagnostics and monitoring leads to customized therapy protocols and encourages regional dominance in innovation. Cooperation between regional biopharmaceutical firms and international institutions ensures clinical testing of new drugs. Integrative care models and physician education facilitate evidence-based therapy protocols and post-therapy follow-ups.
Advanced diagnostic platforms, a strong biotechnology sector, and proactive clinician networks are promoting steady Graves disease treatment adoption across South Korea. Digital health adoption improves telemedicine and patient adherence. Outpatient services facilitate interdisciplinary treatment, while industrial alliances assist in developing commercialization models specific to the region. Government programs promote translational studies and international cooperation, allowing for the assessment of novel treatments locally.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Prevalence Of Graves Disease
With an increase in the global occurrence of Graves disease, there is an increase in the number of people who require medication for the disease. This has caused healthcare professionals to focus on ways of diagnosing and treating the disorder, and since the number of patients increases, the demand for medicines has also increased, which will motivate manufacturers and other organizations to do research on how they can improve their products.
Advancements In Targeted Therapies
Development in specific targeted treatments and better knowledge about autoimmune diseases physiology is propelling research into treatments that will be more specific and safer to use, boosting doctors' confidence in new products. New treatments will encourage companies to invest in drug research, making collaboration between researchers and companies easier, thus increasing product development in the pipeline. Newer products respond to patient needs by offering treatments that are more specific and less risky, which promotes the global Graves disease treatment market outlook.
High Cost Of Advanced Treatments
High pricing involved in the utilization of innovative technologies may discourage the uptake by several patients and may also limit the willingness of the payers to offer coverage, leading to slower uptake. The notion that new technologies come with high costs will prompt the clinician and health care system to opt for the more affordable alternatives, even though this might have its own disadvantages. Economic factors will determine how fast new technologies can get into the market, as the high costs involved are an impediment to their uptake.
Regulatory Approval Complexity and Timelines
The stringent regulatory environment, along with the lengthy process of obtaining approvals, may hinder the timely launch of new products in addition to creating uncertainties for both the drug developer and healthcare provider, which limits market entry speeds. Compliance with varying regulations and collecting data for the same becomes more important than expanding and marketing the drugs, which may discourage investors from entering the market. Consequently, the range of available treatments gets limited.
Request Free Customization of this report to help us to meet your business objectives.
Competitive landscape is defined by incumbent biologics consolidation and targeted innovation from smaller biotechs and digital entrants. Recent M&A that moved market leverage toward large acquirers is reshaping access and pricing. Novel strategies include acquisition of marketed TED assets, one-time local gene therapy development, and AI-driven patient monitoring to improve trial recruitment and differentiation, exemplified by Amgen’s Horizon Therapeutics acquisition, Kriya’s AAV-based TED program, and Thyroscope’s Glandy platform.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, rising prevalence of autoimmune thyroid disorders and increasing awareness and early diagnosis of hyperthyroidism are anticipated to drive the demand for Graves disease treatment going forward. However, high treatment costs, potential side effects of therapies, and limited access to advanced biologics in developing regions are slated to slow down the adoption of Graves disease treatment in the future. North America is slated to spearhead the demand for Graves disease treatment owing to advanced healthcare infrastructure, high diagnosis rates, and availability of innovative therapies such as Teprotumumab. Integration of AI in diagnostic imaging and treatment planning, expansion of biologic therapies, and increasing adoption of tele-endocrinology are anticipated to be key trends driving the Graves disease treatment sector over the coming years.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 2.5 Billion |
| Market size value in 2033 | USD 4.05 Billion |
| Growth Rate | 5.5% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Graves Disease Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Graves Disease Treatment Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Graves Disease Treatment Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Graves Disease Treatment Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Graves Disease Treatment Market size was valued at USD 2.5 Billion in 2024 and is poised to grow from USD 2.64 Billion in 2025 to USD 4.05 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).
Competitive landscape is defined by incumbent biologics consolidation and targeted innovation from smaller biotechs and digital entrants. Recent M&A that moved market leverage toward large acquirers is reshaping access and pricing. Novel strategies include acquisition of marketed TED assets, one-time local gene therapy development, and AI-driven patient monitoring to improve trial recruitment and differentiation, exemplified by Amgen’s Horizon Therapeutics acquisition, Kriya’s AAV-based TED program, and Thyroscope’s Glandy platform. 'Genzyme Corporation', 'AbbVie Inc.', 'Merck & Co., Inc.', 'Eli Lilly and Company', 'Amgen Inc.', 'Novo Nordisk A/S', 'Pfizer Inc.', 'Bristol-Myers Squibb Company', 'Sanofi', 'GlaxoSmithKline plc', 'AstraZeneca', 'Johnson & Johnson', 'Bayer AG', 'Takeda Pharmaceutical Company Limited', 'Medtronic plc', 'Boehringer Ingelheim', 'Teva Pharmaceutical Industries Ltd.', 'Novartis AG', 'Astellas Pharma Inc.', 'Ipsen S.A.'
Increased global prevalence of Graves disease has expanded the pool of patients seeking therapeutic options, prompting healthcare providers to prioritize diagnosis and management pathways. Greater patient numbers elevate demand for established and novel treatments, encouraging investment in clinical research, commercial development, and healthcare infrastructure. This sustained patient driven need motivates pharmaceutical companies to enhance formulation offerings and delivery methods, while clinicians adopt broader treatment guidelines. Collectively, heightened prevalence strengthens market momentum by ensuring continuous utilization and supporting long term strategic planning across stakeholders.
Personalized Care Models: Healthcare providers and specialist clinics are increasingly tailoring treatment plans to individual patient profiles, combining clinical presentation, comorbidity considerations and patient preferences. This shift emphasizes multidisciplinary coordination among endocrinologists, ophthalmologists and mental health professionals to improve adherence and quality of life. Emerging protocols prioritize individualized dosing strategies, shared decision-making and patient education, while manufacturers support targeted therapeutic options and companion diagnostics. Payer dialogues focus on value-based outcomes, encouraging models that align therapy selection with long-term patient-centered goals and ecosystem alignment.
The cooperative/regulatory environment and active patient advocates help support both the development and consistent use of evidence-based treatment guidelines and the implementation of evidence-based management strategies throughout North America.
The antithyroid drugs segment dominates the market as it remains the first-line treatment due to ease of oral administration, strong clinical familiarity, and effectiveness in long-term management of hyperthyroidism.
The targeted biologics segment is the fastest growing, driven by its ability to treat complex and refractory cases with more precise mechanisms of action and improved clinical outcomes.
Major restraints include high treatment costs, side effects of therapies, limited access to advanced biologics in low-income regions, and regulatory approval complexities, which slow down adoption and market expansion.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
